Mutational Testing to Select Novel Targeted Therapies in AML

Slides:

Advertisements

Similar presentations

Monitoring and Management of Adult Relapsed/Refractory Acute Promyelocytic Leukemia.

Advertisements

Improving Survival in Glioblastoma Multiforme

NOACs In Long-term VTE Treatment: A State Of The Art Review

Targeting FLT3 Mutations in Acute Myeloid Leukemia

Advanced NSCLC Without Actionable Mutations

Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome

The Nurse View.

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

The Genomics of Cancer and Molecular Testing:

Mutations and AML: Sampling, Assays, and Interpreting Results

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Current and Future Goals in the Treatment of Relapsed CLL

Goals of Therapy in Relapsed CLL

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Advances in Myeloid Malignancies

Novel and Emerging Approaches to Treating CLL

Counseling Patients About Germline BRCA Mutations

Treatment Decisions in Chemorefractory Follicular Lymphoma

Management Challenges in CLL

Updates in Lymphoma From Recent Congresses

62-year-old Man With Unstable Angina

Individualizing Care in Ovarian Cancer

More Than Meets the Eye.

The Biology Behind BCL2 as a Target in Myeloma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Charting Progress in MS Treatment:

Personalized Therapy in Relapsed or Refractory CLL

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Myeloid Updates From the Summer Congresses

Program Goals Overview Is NEDA a Reasonable Target?

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

The Role of IDH Inhibitors in Hematologic Malignancies

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Implications of Emerging Treatments for Beta-Thalassemia

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Non-Chemotherapy Combinations in CLL

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

The Changing Field of Melanoma: Ipilimumab.

Evaluating BTK Inhibitors in CLL

Critical Decision Points in Insomnia

Assessing New Paradigms in CLL: MRD Negativity

Managing Anemia in Lower-Risk MDS

Incorporating Prostacyclins Into Practice

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Oral Treatment Strategies in CLL

IDH Inhibitors in AML.

AMD Therapy: Where Are We Now and Where Are We Going?

At the Crossroads of Coagulation

Checkpoint Inhibitors in First-Line Advanced NSCLC

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Third-Generation EGFR TKIs

Targeting Apoptosis in AML

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Risk Stratification in MDS

Program. Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML.

Treatment Initiation and Selection in Newly Diagnosed CLL

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Mutational Testing to Select Novel Targeted Therapies in AML

Key Points From de novo AML Genome Atlas

Current Guidelines for Cytogenetic/ Molecular Testing in AML: NCCN

Current Guidelines for Cytogenetic/ Molecular Testing in AML: ELN

Guidelines for Gene Panel Diagnostics

Risk Stratification and Cytogenetic and Molecular Abnormalities in AML

AML: General Treatment Principles

Treatment of AML in Patients < 60 Years (non-APL)

Induction Considerations

Quality of Remission Matters

Relapsed/Refractory AML

Examples of Novel Targeted Therapies in AML

Emerging Targeted Therapies

Emerging Targeted Therapies (cont)

Emerging Targeted Therapies (cont)

Emerging Targeted Therapies (cont)

Emerging Targeted Therapies (cont)

RATIFY Trial

IDH Inhibitors

BCL-2

Venetoclax: BCL-2 Selective Inhibitor

Low-Dose Ara-C Plus Venetoclax

Phase 1b Study of Venetoclax in Combination With HMA

Single-Agent MDM2 Inhibition

Other Emerging Therapies

Integrating Novel Therapies Into Practice: Suggestions and Predictions

Integrating Novel Therapies Into Practice: Suggestions and Predictions (cont)

What Should Be on Your Radar?

What Should Be on Your Radar? (cont)

Abbreviations

Abbreviations (cont)